• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form DEFA14A filed by Certara Inc.

    4/3/26 6:04:32 AM ET
    $CERT
    Computer Software: Prepackaged Software
    Technology
    Get the next $CERT alert in real time by email
    DEFA14A 1 tm261467d3_defa14a.htm DEFA14A

     

     

     

    UNITED STATES 

    SECURITIES AND EXCHANGE COMMISSION 

    Washington, D.C. 20549

     

    SCHEDULE 14A

     

    Proxy Statement Pursuant to Section 14(a) of the 

    Securities Exchange Act of 1934 

    (Amendment No.            )

     

    Filed by the Registrant x

     

    Filed by a Party other than the Registrant ¨

     

    Check the appropriate box:

     

    ¨ Preliminary Proxy Statement

     

    ¨ Confidential, For Use of the Commission Only (as permitted by Rule 14a-6(e)(2))

     

    ¨ Definitive Proxy Statement

     

    x Definitive Additional Materials

     

    ¨ Soliciting Material Pursuant to §240.14a-12

     

    Certara, Inc. 

    (Name of Registrant as Specified In Its Charter)

     

     

    (Name of Person(s) Filing Proxy Statement, if other than the Registrant)

     

    Payment of Filing Fee (Check the appropriate box):

     

      x No fee required.

     

      ¨ Fee paid previously with preliminary materials.
         
      ¨ Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a6(i)(1) and 0-11

     

     

     

     

     

     

    GRAPHIC

    Your Vote Counts! Smartphone users Point your camera here and vote without entering a control number For complete information and to vote, visit www.ProxyVote.com Control # V83962-P44447 *Please check the meeting materials for any special requirements for meeting attendance. CERTARA, INC. C/O BROADRIDGE P.O. BOX 1342 BRENTWOOD, NY 11717 CERTARA, INC. 2026 Annual Meeting Vote by May 13, 2026 11:59 PM ET You invested in CERTARA, INC. and it’s time to vote! You have the right to vote on proposals being presented at the Annual Meeting. This is an important notice regarding the availability of proxy materials for the stockholder meeting to be held on May 14, 2026. Vote Virtually at the Meeting* May 14, 2026 9:00 a.m. Eastern Time Virtually at: www.virtualshareholdermeeting.com/CERT2026 Get informed before you vote View the Notice and Proxy Statement and Annual Report on Form 10-K online at www.proxyvote.com OR you can receive a free paper or email copy of the material(s) by requesting prior to April 30, 2026. If you would like to request a copy of the material(s) for this and/or future stockholder meetings, you may (1) visit www.proxyvote.com, (2) call 1-800-579-1639 or (3) send an email to sendmaterial@proxyvote.com. If sending an email, please include your control number (indicated below) in the subject line. Unless requested, you will not otherwise receive a paper or email copy.

    GRAPHIC

    Vote at www.ProxyVote.com Prefer to receive an email instead? While voting on www.ProxyVote.com, be sure to click “Delivery Settings”. Voting Items Board Recommends V83963-P44447 THIS IS NOT A VOTABLE BALLOT This is an overview of the proposals being presented at the upcoming stockholder meeting. Please follow the instructions on the reverse side to vote these important matters. 1. To elect the three Class III directors named in our Proxy Statement to hold office until the 2029 Annual Meeting of Stockholders and until their respective successors have been duly elected and qualified. For Nominees: 01) Arjun Bedi 02) Stephen McLean 03) Jon Resnick 2. Ratification of the selection of RSM US LLP as our independent registered public accounting firm for 2026. For 3. A non-binding advisory vote to approve the compensation of our named executive officers for the most recently completed fiscal year. For NOTE: To transact such other business as may properly come before the Annual Meeting or any adjournment thereof.

     

    Get the next $CERT alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $CERT

    DatePrice TargetRatingAnalyst
    3/6/2026$8.00Overweight → Equal Weight
    Barclays
    2/27/2026$10.00Buy → Hold
    Craig Hallum
    1/6/2026$13.00Market Perform → Outperform
    Leerink Partners
    11/21/2025$10.00Buy
    Rothschild & Co Redburn
    11/13/2025$9.00Market Perform
    BMO Capital Markets
    9/29/2025$16.00Buy
    Craig Hallum
    7/3/2025$16.00Equal-Weight
    Morgan Stanley
    5/8/2025$14.00Equal Weight → Overweight
    Barclays
    More analyst ratings

    $CERT
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Certara downgraded by Barclays with a new price target

    Barclays downgraded Certara from Overweight to Equal Weight and set a new price target of $8.00

    3/6/26 8:25:25 AM ET
    $CERT
    Computer Software: Prepackaged Software
    Technology

    Certara downgraded by Craig Hallum with a new price target

    Craig Hallum downgraded Certara from Buy to Hold and set a new price target of $10.00

    2/27/26 8:32:38 AM ET
    $CERT
    Computer Software: Prepackaged Software
    Technology

    Certara upgraded by Leerink Partners with a new price target

    Leerink Partners upgraded Certara from Market Perform to Outperform and set a new price target of $13.00

    1/6/26 8:38:03 AM ET
    $CERT
    Computer Software: Prepackaged Software
    Technology

    $CERT
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Certara to Participate in Upcoming Investor Conferences

    RADNOR, Pa., May 18, 2026 (GLOBE NEWSWIRE) -- Certara, Inc. (NASDAQ:CERT), a global leader in model-informed drug development, today announced that Company management will participate in the following investor conferences: RBC CM Global Healthcare ConferenceDate and Time: Tuesday, May 19 at 9:30 a.m. ET William Blair's 46th Annual Growth Stock ConferenceDate: Tuesday, June 2 Jefferies Global Healthcare ConferenceDate: Wednesday, June 3 at 1:20 p.m. ET Live webcasts for the RBC and Jefferies conferences will be available on Certara's investor relations website at https://ir.certara.com and will be available for replay for at least 90 days thereafter. About CertaraCertara accelerates me

    5/18/26 4:15:00 PM ET
    $CERT
    Computer Software: Prepackaged Software
    Technology

    Certara Reports First Quarter 2026 Financial Results

    RADNOR, Pa., May 11, 2026 (GLOBE NEWSWIRE) -- Certara, Inc. (NASDAQ:CERT), a global leader in model-informed drug development, today reported its first quarter 2026 financial results. First Quarter Highlights: Revenue was $106.9 million, compared to $106.0 million in the first quarter of 2025, representing growth of 1%. Software revenue was $49.7 million, compared to $46.4 million in the first quarter of 2025, representing growth of 7%.Services revenue was $57.2 million, compared to $59.6 million in the first quarter of 2025, representing a decrease of 4%. Net loss was $8.8 million, compared to a net income of $4.7 million in the first quarter of 2025, representing a decrease of 285%.A

    5/11/26 6:25:00 AM ET
    $CERT
    Computer Software: Prepackaged Software
    Technology

    Altasciences and Certara Announce Strategic Partnership to Accelerate Early Drug Development

    Altasciences, a fully integrated drug development solution company, and Certara (NASDAQ:CERT), a global leader in model-informed drug development (MIDD), today announced a strategic partnership to accelerate early-phase development programs. Fewer than half of preclinical drug candidates successfully reach first-in-human trials. Failures are driven by toxicity, poor pharmacokinetics, lack of efficacy, and challenges translating results from animals to humans. Many of these risks can be mitigated through a fully integrated model-informed drug development approach. Building on Altasciences' Acceleration Platform, the integration of Certara's strategic drug development services and biosimu

    5/7/26 8:00:00 AM ET
    $CERT
    Computer Software: Prepackaged Software
    Technology

    $CERT
    SEC Filings

    View All

    SEC Form 8-K filed by Certara Inc.

    8-K - Certara, Inc. (0001827090) (Filer)

    5/15/26 4:31:48 PM ET
    $CERT
    Computer Software: Prepackaged Software
    Technology

    SEC Form 10-Q filed by Certara Inc.

    10-Q - Certara, Inc. (0001827090) (Filer)

    5/11/26 6:33:56 AM ET
    $CERT
    Computer Software: Prepackaged Software
    Technology

    Certara Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Other Events, Financial Statements and Exhibits

    8-K - Certara, Inc. (0001827090) (Filer)

    5/11/26 6:28:19 AM ET
    $CERT
    Computer Software: Prepackaged Software
    Technology

    $CERT
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    CHIEF EXECUTIVE OFFICER Feehery William F bought $200,000 worth of shares (24,096 units at $8.30), increasing direct ownership by 1% to 2,360,769 units (SEC Form 4)

    4 - Certara, Inc. (0001827090) (Issuer)

    11/12/25 4:44:55 PM ET
    $CERT
    Computer Software: Prepackaged Software
    Technology

    $CERT
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Human Resources Officer Anhalt Rona converted options into 7,147 shares and covered exercise/tax liability with 2,241 shares, increasing direct ownership by 41% to 16,789 units (SEC Form 4) (withholding tax)

    4 - Certara, Inc. (0001827090) (Issuer)

    6/2/26 5:15:27 PM ET
    $CERT
    Computer Software: Prepackaged Software
    Technology

    SVP and General Counsel Corcoran Daniel converted options into 22,830 shares and covered exercise/tax liability with 12,103 shares, increasing direct ownership by 50% to 32,046 units (SEC Form 4) (for tax liability)

    4 - Certara, Inc. (0001827090) (Issuer)

    6/2/26 5:14:47 PM ET
    $CERT
    Computer Software: Prepackaged Software
    Technology

    Director Bedi Arjun converted options into 5,547 shares (SEC Form 4)

    4 - Certara, Inc. (0001827090) (Issuer)

    5/15/26 4:28:16 PM ET
    $CERT
    Computer Software: Prepackaged Software
    Technology

    $CERT
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by Certara Inc.

    SC 13G - Certara, Inc. (0001827090) (Subject)

    11/14/24 8:38:56 AM ET
    $CERT
    Computer Software: Prepackaged Software
    Technology

    Amendment: SEC Form SC 13G/A filed by Certara Inc.

    SC 13G/A - Certara, Inc. (0001827090) (Subject)

    10/4/24 10:25:50 AM ET
    $CERT
    Computer Software: Prepackaged Software
    Technology

    SEC Form SC 13G/A filed by Certara Inc. (Amendment)

    SC 13G/A - Certara, Inc. (0001827090) (Subject)

    2/13/24 5:01:03 PM ET
    $CERT
    Computer Software: Prepackaged Software
    Technology

    $CERT
    Financials

    Live finance-specific insights

    View All

    Certara Reports First Quarter 2026 Financial Results

    RADNOR, Pa., May 11, 2026 (GLOBE NEWSWIRE) -- Certara, Inc. (NASDAQ:CERT), a global leader in model-informed drug development, today reported its first quarter 2026 financial results. First Quarter Highlights: Revenue was $106.9 million, compared to $106.0 million in the first quarter of 2025, representing growth of 1%. Software revenue was $49.7 million, compared to $46.4 million in the first quarter of 2025, representing growth of 7%.Services revenue was $57.2 million, compared to $59.6 million in the first quarter of 2025, representing a decrease of 4%. Net loss was $8.8 million, compared to a net income of $4.7 million in the first quarter of 2025, representing a decrease of 285%.A

    5/11/26 6:25:00 AM ET
    $CERT
    Computer Software: Prepackaged Software
    Technology

    Certara to Report First Quarter 2026 Financial Results on May 11th, 2026

    RADNOR, Pa., April 09, 2026 (GLOBE NEWSWIRE) -- Certara, Inc. (NASDAQ:CERT), a global leader in model-informed drug development, today announced that it will release financial results for the first quarter of 2026 before market open on Monday, May 11th, 2026. Company management will host a conference call to discuss financial results at 8:30AM ET. Investors interested in listening to the conference call are required to register online. It is recommended to register at least one day in advance. A live and archived webcast of the event will be available on the "Investors" section of the Certara website at https://ir.certara.com/. About CertaraCertara accelerates medicines using biosimulat

    4/9/26 4:15:00 PM ET
    $CERT
    Computer Software: Prepackaged Software
    Technology

    Certara Reports Fourth Quarter 2025 Financial Results; Provides Full Year 2026 Guidance

    FY 2025 Revenue of $418.8M (9% growth) and Adj. EBITDA of $134.5M (10% growth) Fourth Quarter Revenue of $103.6M (3% growth) and Adj. EBITDA of $32.5M (-3% decline) FY 2026 Revenue Growth of 0-4% FY 2026 Adjusted EBITDA Margin of 30-32% FY 2026 Adjusted Diluted EPS of $0.44-$0.48 RADNOR, Pa., Feb. 26, 2026 (GLOBE NEWSWIRE) -- Certara, Inc. (NASDAQ:CERT), a global leader in model-informed drug development, today reported its fourth quarter and full fiscal year 2025 financial results. Fourth Quarter Highlights: Appointment of Jon Resnick as Chief Executive Officer and Member of the Board of Directors, effective January 1st, 2026.Revenue was $103.6 million, compared to $100.4 million i

    2/26/26 6:00:00 AM ET
    $CERT
    Computer Software: Prepackaged Software
    Technology

    $CERT
    Leadership Updates

    Live Leadership Updates

    View All

    Certara Appoints Jon Resnick as Chief Executive Officer

    Resnick brings decades of leadership experience in health sciences, business operations, strategy, innovation and commercial growth William Feehery to step down as CEO on December 31, 2025 Company reaffirms full year 2025 financial outlook RADNOR, Pa., Dec. 11, 2025 (GLOBE NEWSWIRE) -- Certara, Inc. (NASDAQ:CERT), a global leader in model-informed drug development, announced today that it has appointed Jon Resnick as its next Chief Executive Officer and member of Certara's Board of Directors, effective January 1, 2026, succeeding William F. Feehery, who will at that point serve as an external advisor during a transition period. Resnick brings over 20 years of experience with IQVIA, a g

    12/11/25 6:00:00 AM ET
    $CERT
    Computer Software: Prepackaged Software
    Technology

    Certara Appoints Dr. Chris Bouton as Chief Technology Officer to Advance AI in-silico Drug Discovery and Development Platform

    RADNOR, Pa., July 31, 2025 (GLOBE NEWSWIRE) -- Certara, Inc. (NASDAQ:CERT), a global leader in model-informed drug development, today announced the appointment of Christopher Bouton, Ph.D., as Chief Technology Officer. In this role, Bouton will lead technology strategy and development of a next-generation integrated model-informed drug development (MIDD) platform, which is enabled by generative AI and advances in biosimulation technology. Dr. Bouton was the founder and CEO of Vyasa Analytics, acquired by Certara in 2022. Vyasa provided scalable deep-learning software, which allows Certara software to make new predictions and answer complex questions across structured and unstructured data

    7/31/25 4:15:00 PM ET
    $CERT
    Computer Software: Prepackaged Software
    Technology

    Certara Appoints Dr. Adrian McKemey as President of Drug Development Solutions

    RADNOR, Pa., March 05, 2025 (GLOBE NEWSWIRE) -- Certara, Inc. (NASDAQ:CERT), a global leader in model-informed drug development, today announced the appointment of Adrian McKemey, Ph.D. as President of Drug Development Solutions, effective March 3rd, 2025. In this role, McKemey will lead Certara's global team of drug development scientists. Adrian joins Certara after serving as head of Enterprise Transformation at IQVIA and Senior Vice President and Head of the R&D Strategy Solutions at Quintiles. He has over 25 years of experience in research and development roles where he focused on business transformation, portfolio management and R&D strategies. Before IQVIA, he was a Principal with t

    3/5/25 4:15:00 PM ET
    $CERT
    Computer Software: Prepackaged Software
    Technology